Clinical Pharmacokinetics

, Volume 16, Issue 3, pp 129–133 | Cite as

Clinical Significance of Differences in Bioavailability of Medroxyprogesterone Acetate Preparations

  • A. D. Stockdale
  • A. Y. Rostom
Leading Article

Keywords

Metastatic Breast Cancer Advanced Breast Cancer Medroxyprogesterone Acetate Cancer Treatment Report Cuna 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adlercreutz H, Eriksen PB, Christensen MS. Plasma concentration of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects. Journal of Pharmacology and Bio-medical Analysis 1: 153–162, 1983CrossRefGoogle Scholar
  2. Beex L, Burghout SJ, Van Turnhout J, Breed W, Hillen H, et al. Oral vs IM administration of high dose medroxyprogesterone acetate in pre-treated patients with advanced breast cancer. Cancer Treatment Reports 71: 1151–1156, 1987PubMedGoogle Scholar
  3. Blossey HC, Bartsch HH, Kanne D, Koebberling J, Nagel GA. The pharmacokinetics of high dose medroxyprogesterone acetate in the therapy of advanced breast cancer. Cancer Chemotherapy and Pharmacology 8: 77–81, 1982PubMedCrossRefGoogle Scholar
  4. Camaggi CM, Strocchi E, Constanti B, Beghelli P, Ferrari P, et al. Medroxyprogesterone acetate bioavailability after high dose intraperitoneal administration in advanced cancer. Cancer Chemotherapy and Pharmacology 14: 232–234, 1985PubMedGoogle Scholar
  5. Camaggi CM, Strocchi E, Giovannini M, Angelelli B, Constanti B, et al. Medroxyprogesterone acetate (MPA) plasma levels after multiple high-dose administration in advanced cancer patients. Cancer Chemotherapy and Pharmacology 11; 19–22, 1983PubMedCrossRefGoogle Scholar
  6. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, et al. Randomised trial of low versus high dose medroxyprogesterone acetate in the induction treatment of post-menopausal patients with advanced breast cancer. Journal of Clinical Oncology 2: 414–419, 1984PubMedGoogle Scholar
  7. De Lena M, Villa S, Di Fronzo G. Therapeutic activity of medroxyprogesterone acetate in metastatic breast cancer: a correlation between estrogen receptors and various dosages. Recent Results in Cancer Research 91: 243–247, 1984PubMedCrossRefGoogle Scholar
  8. Della Cuna GR, Calciati A, Strada MRB, Bumma C, Campio L. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose response evaluation. Tumori 64: 143–149, 1978PubMedGoogle Scholar
  9. Falkson G, Falkson HC. A phase II study of high dose medroxyprogesterone acetate in advanced breast cancer. Cancer Chemotherapy and Pharmacology 11: 16–18, 1983PubMedGoogle Scholar
  10. Gallagher CJ, Cairnduff F, Smith IE. High dose versus low dose medroxyprogesterone acetate: a randomised trial in advanced breast cancer. European Journal of Cancer and Clinical Oncology 23: 1895–1900, 1987CrossRefGoogle Scholar
  11. Ganzina F. High dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori 65: 563–585, 1979PubMedGoogle Scholar
  12. Goss PE, Ashley S, Powles TJ, Coombes RC. High dose medroxyprogesterone acetate in heavily pre-treated patients with metastatic breast cancer. Cancer Treatment Reports 70: 777–779, 1986PubMedGoogle Scholar
  13. Gupta C, Osterman J, Santen R, Bardin CW. In vitro metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women. Journal of Clinical Endocrinology and Metabolism 48: 816–820, 1979PubMedCrossRefGoogle Scholar
  14. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, et al. Assessment of response to therapy in advanced breast cancer. A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39: 1289–1293, 1977PubMedCrossRefGoogle Scholar
  15. Hedley DW, Christie M, Weatherby RP, Caterson ID. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function and tumour response in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 14: 112–115, 1985PubMedCrossRefGoogle Scholar
  16. Hortobagyi GN, Buzdar AU, Yap HY, Hug V, Pinnamaneni K, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment 5: 321–326, 1985PubMedCrossRefGoogle Scholar
  17. Johansson EDB, Johansen PB, Rasmussen SN. Medroxyprogesterone acetate pharmacokinetics following oral high dose administration in humans. A bioavailability evaluation of a new MPA tablet formulation. Acta Pharmacologica Toxicologica 58: 311–317, 1986CrossRefGoogle Scholar
  18. Johnson JR, Priestman TJ, Fotherby K, Kelly KA, Priestman SG. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer. British Journal of Cancer 50: 363–366, 1984PubMedCrossRefGoogle Scholar
  19. Mahlke M, Grill HJ, Knapstein P, Wiegand U, Pollow K. Oral high-dose medroxyprogesterone acetate (MPA) treatment: control/MPA/ serum profiles in relation to breast cancer regression. Oncology 42: 144–149, 1985PubMedCrossRefGoogle Scholar
  20. Martin F, Jarvenpaa P, Kosunen K, Somers C, Lindstrom B, et al. Ring-A reduction of medroxyprogesterone acetate (17 alpha acetoxy-6-alpha methyl-4-pregnene-3,20-dione) (MPA) in biological systems. Journal of Steroid Biochemistry 12: 491–497, 1980PubMedCrossRefGoogle Scholar
  21. Mathrubutham M, Fotherby K. Medroxyprogesterone acetate in human serum. Journal of Steroid Biochemistry 14: 783–786, 1981PubMedCrossRefGoogle Scholar
  22. Miller AA, Becher R, Schmidt CG. Plasma concentrations of medroxyprogesterone acetate and megestrol acetate during long-term follow-up in patients treated for metastatic breast cancer. Journal of Cancer Research and Clinical Oncology 114: 186–190, 1988PubMedCrossRefGoogle Scholar
  23. Mould GP, Read J, Bye A. A comparison of the HPLC and RIA measurement of medroxyprogesterone acetate. Journal of Pharmaceutical and Biomedical Analysis, in press, 1988Google Scholar
  24. Nemoto T, Patel J, Rosner D, Dao TL. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Journal of Surgical Oncology 32: 211–213, 1986PubMedCrossRefGoogle Scholar
  25. Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treatment Reports 62: 499–504, 1978PubMedGoogle Scholar
  26. Pannuti F, Martoni A, Dimarco AR, Piana E, Saccani F, et al. Prospective randomised clinical trial of two different high dosages of medroxyprogestrone acetate (MAP) in the treatment of metastatic breast cancer. European Journal of Cancer 15: 593–601, 1979PubMedCrossRefGoogle Scholar
  27. Paridaens R, Becquart D, Michel J, Vanderlinden B, Longueville J, et al. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. Anticancer Research 6: 1089–1094, 1986PubMedGoogle Scholar
  28. Salimtschik M, Mouridsen HT, Loeber J, Johansson E. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes. Cancer Chemotherapy and Pharmacology 4: 267–269, 1980PubMedCrossRefGoogle Scholar
  29. Stockdale AD, Chapman D, Mould GP, Rostom AY. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations. Cancer Treatment Reports 71: 813–815, 1987PubMedGoogle Scholar
  30. Stoll BA. Progestin therapy of breast cancer: comparison of agents. British Medical Journal 3: 338–341, 1967PubMedCrossRefGoogle Scholar
  31. Sturm G, Schulz KD. MPA assays: measurement of plasma MPA levels in high-dose MPA-treated patients. In Pellegrini et al. (Eds) Role of medroxyprogesterone in endocrine-related tumours, Vol. 3, pp. 23–42, Raven Press, New York, 1984Google Scholar
  32. Tamassia V, Battaglia A, Ganzina F, Isetta AM, Sacchetti G, et al. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Cancer Chemotherapy and Pharmacology 8: 151–156, 1982PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • A. D. Stockdale
    • 1
  • A. Y. Rostom
    • 1
  1. 1.Regional Centre for Radiotherapy and OncologySt Luke’s HospitalGuildfordEngland

Personalised recommendations